---
schema_version: "secwatch.filing_event.v1"
accession: "0001503274-25-000029"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:32:15.642930+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quanterix Q4 2024 revenue $35.2M (+11% YoY); FY 2025 guidance $140-146M

## Summary
- Q4 revenue $35.2M, up 11% YoY; net loss $11.6M vs $8.8M prior year.
- Full-year 2024 revenue $137.4M (+12%); net loss $38.5M improved $10.2M.
- Ended 2024 with $291.7M cash; 2025 cash usage guided at $55-65M (incl. $20M EMISSION payment).
- FY 2025 revenue outlook $140-146M (2-6% growth) excluding Lucent Diagnostics and Akoya impact.
- Simoa ONE instrument launch planned by end-2025; FDA breakthrough designation for LucentAD Complete.

## SEC filing metadata
- accession: 0001503274-25-000029
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000029/0001503274-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000029/qtrx-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001503274-25-000029
- JSON: https://secwatch.observer/filing/0001503274-25-000029.json
- Plain text: https://secwatch.observer/filing/0001503274-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.